Clinical trial
A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
NCT01908010 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
- Lead sponsor
- AbbVie
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2013
- Completion date
- November 30, 2013
- Enrollment
- 20 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
alzheimer's disease